Gurm, Hitinder S <br/><br/>
A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.  [electronic resource] 

 -  Circulation. Cardiovascular interventions  Jun 2009 
 - 230-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Meta-Analysis 
<br/><br/><label>ISSN: </label>1941-7632 
<br/><br/><label>Standard No.: </label>10.1161/CIRCINTERVENTIONS.108.847996  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Aged<br/>Angioplasty, Balloon, Coronary--adverse effects<br/>Antibodies, Monoclonal--adverse effects<br/>Eptifibatide<br/>Female<br/>Hemorrhage--chemically induced<br/>Humans<br/>Immunoglobulin Fab Fragments--adverse effects<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--mortality<br/>Odds Ratio<br/>Peptides--adverse effects<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Randomized Controlled Trials as Topic<br/>Recurrence<br/>Risk Assessment<br/>Risk Factors<br/>Thrombosis--etiology<br/>Time Factors<br/>Tirofiban<br/>Treatment Outcome<br/>Tyrosine--adverse effects